February 09, 2018
A new tool for improving uterine transplant surgery
Study demonstrates the first use of biomedical photonics in gynecological surgery
Future Science Group (FSG) today announced the publication of an article in Future Science OA demonstrating the first use of multispectral imaging in gynecology, in a uterine transplant setting.
Uterine transplantation aims to remedy absolute uterine factor infertility, or the absence of a womb, allowing pregnancy. The first reported successful pregnancy following uterine transplantation was in 2014.
Currently, there is an absence of real-time, functional and molecular data during, pre- and post-surgery. This is particularly apparent in uterine transplants where there is a need to assess the level of ischemia and reperfusion injury during and post-transplantation, and prior to any potential pregnancy.
“We wanted to explore avenues that may potentially be better at evaluating tissue and organ perfusion than existing methods,” commented Srdjan Saso (Imperial College London, UK). “Multi-spectral imaging (MSI), an example of biomedical photonics, proved effective at giving us a real-time, spatial picture of graft perfusion and therefore tissue viability.”
Biomedical photonics is able to process data concerning hemoglobin concentration and oxygen saturation in a noninvasive manner in real time. The study compared two photonic applications using animal models: pulse oximetry and MSI. MSI was able to map oxygen saturation over the entire graft, demonstrating advantages over pulse oximetry and showing promise for use in humans.
“The ability to obtain such results using MSI will allow the surgical team to act appropriately during pelvic surgery and most importantly intra-operatively in order to rectify any issues,” explained Saso. MSI therefore has the potential to become an effective tool in transplant surgery.
“[Our] next goal is to evaluate the effect of hypo-oxygenation on long-term organ function. We will evaluate uterine viability with various functional long-term variables to confirm the utility of MSI,” he concluded.
The full research article is open access and available here: https://www.future-science.com/doi/10.4155/fsoa-2017-0129
About Future Science OA
Launched in March 2015, Future Science OA is a gold open access, biomedical journal from the Future Science Group. It publishes articles covering the latest research of application to human health, and utilizes a CC-BY license. Future Science OA embraces the importance of publishing all good-quality research with the potential to further the progress of medical science. Both negative and early-phase research is considered. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.